Pomerantz Law Firm Investigates Securities Fraud Claims Against Altimmune, Inc. Amid Recent Stock Plunge

Investigation of Altimmune, Inc. by Pomerantz Law Firm

Pomerantz LLC, a distinguished law firm specializing in corporate and securities class action litigation, is currently investigating claims on behalf of investors in Altimmune, Inc. (NASDAQ: ALT). The inquiry was initiated following a troubling announcement by the company regarding the results from the Phase 2b trial of pemvidutide aimed at treating metabolic dysfunction-associated steatohepatitis (MASH).

On June 26, 2025, Altimmune reported the topline results from this clinical trial, which the Company maintained were "positive." However, a deeper analysis revealed concerning findings regarding the drug's efficacy. The report indicated that the improvements in fibrosis, a key indicator of the drug's success, were 31.8% and 34.5% for the two doses tested (1.2 mg and 1.8 mg). In contrast, the placebo group showed a 25.9% improvement. Notably, these differences were deemed not statistically significant by the company’s reporting standards, potentially obscuring the true efficacy of pemvidutide and raising questions about the transparency of the results.

As a direct response to this news, Altimmune’s stock saw an alarming decline, plummeting by 53.18% to close at $3.61 per share, marking a loss of $4.10 within a single trading day. This drastic fall has drawn the attention of legal experts and investors alike, leading to the current investigation by Pomerantz. The firm is committed to assessing whether Altimmune's management, including its directors and officers, may have engaged in securities fraud or other illegal business practices.

Investors who believe they have been affected by the company’s recent disclosures or actions are encouraged to reach out to Pomerantz for consultation. As legal precedents hold that shareholders may be entitled to recover losses suffered as a result of misleading statements or omissions by corporate entities, those with potential claims are urged to connect with the firm’s representative, Danielle Peyton. Contact can be made via email or by telephone.

Over the last 85 years, Pomerantz has established itself as a powerful advocate for victims of corporate misconduct and securities fraud, successfully securing numerous multimillion-dollar settlements for its clients. The firm operates on a global scale with offices in major cities including New York, Chicago, and London, ensuring a broad reach in addressing the rights and concerns of investors.

This investigation not only illuminates the complexities of navigating financial markets but also serves as a reminder for investors to remain vigilant about corporate communications and their potential implications.

For those interested in joining the class action or wishing to learn more about this ongoing investigation, further information is available through Pomerantz’s website or by direct inquiry.

Disclaimer: The information provided by Pomerantz LLP does not guarantee any specific results and is intended for informational purposes only. Potential investors should conduct their own research before initiating any legal action.